eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
5/2018
vol. 10
 
Share:
Share:
more
 
 
Original paper

High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: an effective salvage option

Rajendra Bhalavat, Vibhay Pareek, Manish Chandra, Lalitha Nellore, Karishma George, Dipalee Borade, Ketan Kalariya, Zaiba Moosa, Amrita Srivastava, Navaneeth Reddy, Ankita Kapoor, Darshana Kawale, Nandakumar P., Pratibha Bauskar

J Contemp Brachytherapy 2018; 10, 5: 425–430
Online publish date: 2018/10/15
Article file
- high-dose-rate.pdf  [0.65 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Purpose

Head and neck malignancy management has seen many advancements; nevertheless, approximately 20-50% of patients are diagnosed with loco-regional recurrence within first two years [1,2]. Surgery forms the major treatment modality but can be possible in only 20% patients, leading to overall 5-year survival of 20% to 30% [3,4,5,6,7]. External beam radiation therapy (EBRT) can lead to severe local toxicities in view of reirradiation to the primary. High-dose-rate brachytherapy (HDR-BRT) however, can deliver a high dose directly to the target volume, and provides the advantage of rapid dose fall-off, thereby allowing for sparing of normal tissue [8,9,10].
With the advent of 3DCRT (3D conformal radiation therapy) and IMRT (intensity modulated radiation therapy), as more conformal treatment techniques, there has been a rise in the publications presenting results with the use of these treatment techniques, demonstrating the survival outcomes and toxicity profiles associated with reirradiation in head and neck malignancies. However, in most cases, even these techniques cannot prevent the dose fall off to the surrounding normal tissue, thus leading to acute and late toxicities, and sometimes even compromising the doses to target volumes itself leading to future recurrences and failures.
High-dose-rate brachytherapy offers significant advantages over conventional LDR (low-dose-rate) brachy­therapy by reducing concerns of radiation safety for the staff during hospitalization and provides the clinician with a greater control over the dose distribution by using computer optimized dwell times within the individual catheters. With HDR-BRT, dosimetrically equivalent or superior outcomes compared to LDR brachytherapy and EBRT for gynecological tumors and other locations have been achieved [11,12]. However, the same data in head and neck malignancies and the use of interstitial brachytherapy is minimal. In this study, we present our results and experience with retrospective analysis demonstrating our recent experience in the use of HDR-BRT in management of recurrent head and neck malignancies.

Material and methods

Patient characteristics

From January 2009 to June 2016, twenty-five patients with histopathologically proven recurrent head and neck malignancies were treated with HDR-BRT at Jupiter Hospital, Thane, India. The primary treatment characteristics and patient characteristics are shown in Table 1. Most of the patients had recurrence in the region of previous EBRT or surgery. Out of these 25 patients, 10 were recurrences in oral cavity and 15 in the oropharynx. The patients were evaluated for surgery and found to be ineligible for varied reasons, therefore chosen for radiation therapy with HDR-BRT. There were 14 males and 11 females who underwent reirradiation with HDR-BRT. The median age of these patients was 57 years (range: 34-76 years). In view of larger primary tumors, the patients underwent external beam radiation first, followed by brachytherapy boost. Thus, the study consisted of 18 patients who underwent radical BRT and 7 patients who underwent brachytherapy boost following EBRT. The treatment characteristics are shown in Table 2.

Brachytherapy

The implant procedure was performed under general anesthesia. A nasogastric tube was placed for feeding during treatment. A straight stainless-steel needle was introduced through the sub-mental skin with respect to the site and traversed through the floor of mouth or implanting organ, exited at the other end of operative bed. Subsequent needles passed next to the first one as needed with respect to number of lines and planes, in order to keep interval distance of 14-16 mm between them, according to the need to cover the target. A plastic catheter was threaded through each needle and then, the needle was removed, leaving the catheter in place. The number of catheters varied according to the dimension of the target (Figure 1). The plastic catheters were placed in the operative bed as near parallel as possible at 14 to 16 mm intervals, taking care of peripheral fall-off with a security margin of 10 mm in all directions around the target, using modified technique. The catheters were held to the skin exit points with plastic buttons [13,14]. This implantation technique was used for the various HNC sites. Prophylactic tracheostomy was not done routinely, except for one patient, where lingual surface of epiglottis was involved. After implantation, all patients underwent a computed tomography (CT) scan, with a slice thickness of 3 mm for three-dimensional (3D) treatment planning. Intravenous contrast was used when necessary to visualize the carotid vessels. The CT study was transferred to the Flexiplan system (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden). PTV (planning target volume) and OAR (organ at risk) were contoured and catheters were reconstructed. The treatment planning process was done by computer-assisted dose optimization (Figure 1). The prescribed dose was in the range of 3.5-4.5 Gy per fraction, depending on the site and status of the disease. Fractions were given twice a day with 6 hours apart (median: 10 fractions). The dose parameters were assessed through DVH (dose volume histogram) in percentage. Prescribed and reported doses were specified by D90 (dose received by 90% of the volume), as determined by DVH. The implant was planned after 2-3 weeks of completion of EBRT. In cases where BRT was used as a boost, median gap between external and implant was 21 days.
The implant tubes were removed after planned BRT doses were delivered. Total dose (EBRT/BRT) was kept within tolerance levels and has been assessed by estimating biologically equivalent doses (BED) [8,9]. The median dose with radical BRT was 40.5 Gy, and the dose with BRT boost was 27 Gy. The median dose to primary target volume with EBRT was 50 Gy (range: 46-50 Gy). The median implant volume was 85 cc (range: 38-240 cc). Overall, the median number of fractions were 10 (range: 6-12).

Follow-up

Patients underwent follow-up evaluation at every 4 weeks for the first 6 months, every 3 months for the next 6 months, every 6 months for the next 3 years, and annually thereafter. Biopsy was avoided unless it was essential to confirm residual/re-recurrent disease. Overall, follow-up ranged from 8 to 50 months (median: 25 months) for all patients. Twenty patients reached the two-year follow-up and of these, 6 patients reached the five-year follow-up; these patients were alive at the time of reporting in December 2017. The patients were followed-up with routine investigations including complete blood counts, chest X-ray, and ultrasonography of the neck. In suspicious cases, CT of the neck was done.

Statistical analysis

Statistical analysis was performed using SPSS 17.0 (Statistical Package for Social Sciences 17.0 for Windows) statistical software. Survival results were calculated using the Kaplan-Meier method and log-rank test. The time origin was the date of the first HDR-BRT procedure. The endpoint of overall survival (OS) was death from any cause. The endpoint of disease-free survival (DFS) was any type of recurrence (e.g., failure at the primary site or regional lymph nodes, distant metastasis). The endpoint of interest from local control (LC) was defined as tumor regrowth in the treated area with BRT or in an adjacent region (e.g., failure at the primary site or regional lymph nodes). The patient DFS and OS were calculated from the last date of their follow-up. Toxicity assessment was done using the RTOG toxicity assessment scale, and late toxicities were defined as features persisting or occurring beyond 90 days.

Results

Overall survival

The median survival calculated for patients who underwent reirradiation with HDR-BRT at 1- and 2-year overall survival was found to be 77% and 68%, respectively. The median follow-up was 25 months. There was a difference in the survival rates in radical versus boost arm as shown in Figure 2.

Local control

The local control rates calculated at 1- and 2-year follow-up were found to be 84% and 75%, respectively. The median time to development of recurrence was found to be 9 months, and was found to be seen more with a larger tumor implant (CTV > 85 cc) and more common in the EBRT + BRT arm. The local control rate with radical BRT vs. BRT as boost following EBRT was found to be significant (2-year LCR 62% vs. 85%; p < 0.02). Similarly, the disease specific survival was found to be 74% and 67%, respectively, at 1- and 2-year follow-up.

Toxicity

The late toxicities were assessed as per the Radiation Therapy Oncology Group (RTOG) scale on each follow-up of the patient, and late toxicities were defined as those occurring beyond 90 days. Most of the toxicities noted were grade 1 or 2 and only 2% grade 3 toxicity were noted in the form of taste alteration. No grade 4 toxicities were noted among the patients. Taste alteration (grade 1 and 2, 25% and 12%) and xerostomia (grade 1 and 2, 12% and 4%) were the common toxicities noted. Other significant toxicities noted were dysphagia (grade 1 and 2, 8% and 3%), persistent hoarseness (grade 1 and 2, 3% and 0%), and fibrosis (grade 1 and 2, 5% and 3%). As compared to other studies, there was no incidence of delayed wound healing, cranial nerve palsy, and osteoradionecrosis associated with brachytherapy procedure noted in our study. The cumulative incidence of grade 1 and 2 toxicities at 2-years were 12% and 8%, respectively (Table 3).

Prognostic factors

A univariate Cox analysis on the significant prognostic factors affecting the survival outcomes was performed, including N stage, dose of first irradiation, interval between the two treatments, and implant volume. Pre-treatment volume of 85 cc was found to be significant for favorable overall survival. The overall survival was found to be 26 months and 12 months (p = 0.02), respectively, for implant volume less than and more than 85 cc. Time interval since last treatment was found to be significant for the better local control rates. For interval of less than 15 months, the local control rate was for 10 months as opposed to 31 months in patients who had a treatment interval of more than 15 months (p < 0.01). As expected, lower nodal status disease had better overall survival outcomes (N0-1 vs. N2-3; p = 0.025). The results are depicted in Figure 3.

Dosimetric outcomes

On dosimetric assessment, the dose parameters were evaluated, and optimization assessed. Dose heterogeneity was specified by V100 (the percentage of implant volume receiving 100% of the prescribed dose), V150 (the percentage of implant volume receiving 150% of the prescribed dose), and V200 (the percentage of implant volume receiving 200% of the prescribed dose). In our series, the mean values were: D90 = 4.08 Gy (range: 3.9-4.5 Gy), equivalent to 90.8% of the reference dose of 4.5 Gy; V100 = 94.1% (range: 91-95%); V150 = 24.7% (range: 20-42%); V200 = 10.1% (range: 8-13%). The mean values of homogeneity index (HI) and dose non-uniformity ratio (DNR) were estimated to be 0.71 (range: 0.63-0.75) and 0.39 (range: 0.28-0.42), respectively.
The various dosimetric outcomes are shown in Tables 4 and 5.

Discussion

Our retrospective study was aimed to assess the survival rates and toxicity assessment in the patients undergoing reirradiation with HDR-BRT in head and neck malignancies, both as radical treatment and as a boost following EBRT. The literature review has shown that the role of brachytherapy has been used extensively in the past, but non-sorted consensus has not seen brachytherapy as a modality of choice. The literature review with conventional LDR BRT suggests a 2-year LCR of 30% to 80% [15,16,17].
On comparison of the results in literature with external beam irradiation, the 2-year local control rate varies from 20% to 60% [18,19,20,21]. Even with the advent of technologies and the use of IMRT growing, the toxicity levels with brachytherapy have found to be better compared to the newer treatment advents due to the advantage provided by brachytherapy of sharp dose fall beyond the target volume, thereby sparing the normal tissues without compromising on the target volume. The 2-year overall survival of 68% and local control rate of 75% reported in our study has been comparable to the one reported in the literature. Better control rates with radical brachytherapy implants as compared to EBRT + BRT shows that in microscopic residual and small volume disease, interstitial brachytherapy can prove to be an effective salvage option for head and neck malignancies and provide better survival outcomes with effective target coverage. In our study, median survival calculated for patients who underwent re-irradiation with HDR-BRT at 1 and 2-year overall survival was found to be 77% and 68%, respectively. The median time to development of a recurrence was found to be 9 months, and was found to be more w frequent in larger tumor implant (CTV > 85 cc) and more common in the EBRT + BRT arm. The local control rate with radical BRT vs. BRT as boost following EBRT was found to be significant. (2-year LCR 62% vs. 85%; p < 0.02). The role of brachytherapy as the sole treatment modality can thus be considered in cases with small tumor volume, which eventually would lead to improved local control, disease specific, and overall survival.
Acute and late toxicities form a major limiting factor for opting for radiation therapy as a salvage treatment option in recurrent head and neck malignancies. The toxicities can outweigh the benefits of therapy and result in negative impact on therapeutic index. In the RTOG 99-11 trial, 8% grade 5 (fatal) toxicity and 23% grade 4 acute toxicities were reported [22]. The RTOG 96-10 trial [19] had reported 15% grade 4 and 7% grade 5 toxicities. In our series, cumulative incidence of grade 1 and 2 toxicities at 2-years were 12% and 8%, respectively, and no grade 4 and 5 toxicities were reported. The use of external beam radiation therapy itself can be a difficult modality to be used for salvage option in recurrent head and neck malignancies, as the benefit of therapy can be outweighed by the associated treatment toxicities. Both RTOG studies do not report the delayed toxicities; however, the use of brachytherapy has shown in our series to prevent the severe late toxicities due to the advantage of sharp dose fall off.
The latest report by GEC-ESTRO [23] has reported on the role of HDR-BRT as a salvage option in re-irradiation in the head and neck malignancies. If the patient’s ineligible for surgical salvage, brachytherapy is an acceptable option provided that the coverage of the CTV is adequate and there is not advanced bone invasion, fistula, or limited life expectancy. Brachytherapy in previously full course irradiated regions needs to follow the same principles as primary brachytherapy with strict dose and volume constraints [24,25]. Additionally, interstitial brachytherapy can play an important role in the treatment of lymph node recurrences of head and neck cancer. Using image-guided interstitial HDR-BRT for re-irradiation of recurrent lymph node metastases of head and neck cancer, local control probabilities on the order of approximately 60-70% have been published [26].
The dose of 3.5-4 Gy per fraction has been found to be effective enough to provide good dosimetric coverage and overall survival control, and can be modified as per the stage of the disease with target volume covered. The total dose can be modified as per the treatment interval and the implant volume, which form important prognostic factors for better survival outcomes. Similar dose rates have been used by Hepel et al. [27] and reported a 2-year LCR and survival of 45% and 37%, respectively. Similar outcomes have also been found in another series with a dose rate of 3.2-4 Gy with favorable survival and toxicity outcomes [28]. In our series, we confirm that the dose of 3.5-4 Gy per fraction to a total dose of 30-40 Gy is effective in providing better survival and late toxicity outcomes. Similar doses have been prescribed in various sites of head and neck malignancies treated with HDR brachytherapy as a boost or as radical intent [29].

Conclusions

Re-irradiation of recurrent head and neck cancer is a therapeutic challenge. This retrospective study summarizes our experience with HDR brachytherapy treatment of recurrent head and neck cancer. HDR-BRT seems a viable alternative to surgery and radical EBRT. Although this was a retrospective series using a small number of patients, our study showed that HDR interstitial brachytherapy demonstrated a better local control probability with an acceptable toxicity in diverse treatment settings. This technique offers dosimetric, radiation safety, and patient comfort advantages.

Disclosure

Authors report no conflict of interest.

References

1. Gregoire V, Lefebvre JL, Licitra L et al. ESMO Guidelines Working Group. Squamous cell carcinoma of the head neck: EHNS-ESMO-ESTRO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: 184-186.
2. National Comprehensive Cancer Network. Practice Guidelines: Head and Neck cancer, version 2.2011; 2011 Available from: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
3. Chopra S, Gupta T, Agarwal JP et al. Re-irradiation in the management of isolated neck recurrences: current status and recommendations. Radiother Oncol 2006; 81: 1-8.
4. Tselis N, Ratka M, Vogt HG et al. Hypofractionated accelerated CT-guided interstitial 192Ir-HDR-Brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer. Radiother Oncol 2011; 98: 57-62.
5. McDonald MW, Lawson J, Garg MK et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1292-1298.
6. Parsons JT, Mendenhall WM, Stringer SP et al. Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1995; 32: 605-609.
7. Teman S, Pape E, Janot F et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 62: 1078-1083.
8. Hepel JT, Syed AMN, Puthawala A et al. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005; 62: 1444-1450.
9. Narayana A, Cohen GN, Zaider M et al. High-dose rate brachytherapy in recurrent and previously irradiated head and neck cancers-preliminary results. Brachytherapy 2007; 6: 157-163.
10. Safigholi H, Han DY, Mashouf S et al. Direction modulated brachytherapy (DMBT) for treatment of cervical cancer: a planning study with 192Ir, 60Co, and 169Yb HDR sources. Med Phys 2017; 44: 6538-6547.
11. Kollmeier MA, McBride S, Taggar A et al. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy 2017; 16: 1091-1098.
12. Han DY, Safigholi H, Soliman A et al. Direction modulated brachytherapy for treatment of cervical cancer. II: Comparative planning study with intracavitary and intracavitary – interstitial techniques. Int J Radiat Oncol Biol Phys 2016; 96: 440-448.
13. Bhalavat RL, Laskar S, Saple MP et al. Technique for interstitial brachytherapy of carcinoma of the tongue. J Brachytherapy Int 1998; 14: 179-183.
14. Pierquin B, Wilson JF, Chassagne D et al. Brachytherapy in base of tongue. In: Modern brachytherapy. Pierquin B, Wilson JF, Chassagne D (eds.). Masson Publishing Inc., New York 1987; 147.
15. Vikram B, Strong EW, Shah JP et al. Intraoperative radiotherapy in patients with recurrent head and neck cancer. Am J Surg 1985; 150: 485-487.
16. Park RI, Liberman FZ, Lee DJ et al. Iodine-125 seed implantation as an adjunct to surgery in advanced recurrent squamous cell cancer of the head and neck. Laryngoscope 1991; 101: 405-410.
17. Moscoso JF, Urken ML, Dalton J et al. Simultaneous interstitial radiotherapy with regional or free-flap reconstruction, following salvage surgery of recurrent head and neck carcinoma. Analysis of complications. Arch Otolaryngol Head Neck Surg 1994; 120: 965-972.
18. De Crevoisier R, Bourhis J, Domenge C et al. Full-dose re-irradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998; 16: 3556-3562.
19. Spencer SA, Harris J, Wheeler RH et al. RTOG 96-10: re-irradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001; 51: 1299-1304.
20. Benchalal M, Bachaud JM, Francois P et al. Hyperfractionation in the reirradiation of head and neck cancers. Result of a pilot study. Radiother Oncol 1995; 36: 203-210.
21. Dawson LA, Myers LL, Bradford CR et al. Conformal re-irradiation of recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 377-385.
22. Horwitz EM, Harris J, Langer CJ et al. Phase II study of paclitaxel and cisplatin in combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck: Results of RTOG 99-11. Int J Radiat Oncol Biol Phys 2005; 63: S72-S73.
23. Kovács G, Martinez-Monge R, Budrukkar A et al. GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging-based treatment planning and stepping source technology. Radiother Oncol 2017; 122: 248-254.
24. Strnad V, Melzner W, Geiger M et al. Role of interstitial PDR brachytherapy in the treatment of oral and oropharyngeal cancer. A single-institute experience of 236 patients. Strahlenther Onkol 2005; 181: 762-767.
25. Yamazaki H, Yoshida K, Yoshioka Y et al. High dose rate brachytherapy for oral cancer. J Radiat Res 2013; 54: 1-17.
26. Tselis N, Ratka M, Vogt HG et al. Hypofractionated accelerated CT-guided interstitial 192-Ir HDR brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer. Radiother Oncol 2011; 98: 57-62.
27. Hepel JT, Syed AM, Puthawala A et al. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005; 62: 1444-1450.
28. Martinez-Monge R, Alcalde J, Concejo C et al. Perioperative high-dose-rate brachytherapy in previously irradiated head and neck cancer: Initial results of a phase I/II reirradiation study. Brachytherapy 2006; 5: 203-210.
29. Bhalavat R, Chandra M, Pareek V et al. High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience. J Contemp Brachytherapy 2017; 9: 124-131.
Copyright: © 2018 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe